Stem cell transplantation for T-cell lymphomas in Taiwan

Ya-Ting Hsu, Hui Jen Tsai, Jeffrey S. Chang, Sin-Syue Li, Jih Luh Tang, Su Peng Yeh, Wen Li Hwang, Jin Hwang Liu, Tran Der Tan, Po Nan Wang, Hui Hua Hsiao, Tsai-Yun Chen

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

T-cell lymphomas are generally aggressive malignancies with poor prognosis. There are no standard treatment guidelines for T-cell lymphomas, and the timing of stem cell transplantation (SCT) is not well known. In this study, we investigated the outcomes of Taiwanese patients with T-cell lymphomas after SCT. We retrospectively analyzed 131 patients with T-cell lymphomas receiving SCT (autologous: 90, allogeneic: 41) from 2009 to 2014. More autologous SCT recipients were ALCL or in complete remission, and more allogeneic recipients had advanced disease. 56 patients who were sensitive to chemotherapy underwent SCT as upfront setting. The 2-year PFS and OS rates were 67.0 and 64.5%, respectively. Regarding disease status before transplantation, patients with CR1 had the best outcomes. Among different subtypes, patients with natural killer/T-cell lymphomas showed the worst outcomes, with 2-year OS rate of 23.5%. The OS rates for the other three major subtypes were as follows: 72.9% for ALCL; 75.0% for AITL; and 51.4% for PTCL-NOS. For more rare subtypes, such as ATLL and SPTCL, data from our study show that SCT can be beneficial. We concluded that upfront autologous SCT is feasible and effective for patients with low PIT, and disease status at transplant is the strong predictor of outcome.

Original languageEnglish
Pages (from-to)993-1000
Number of pages8
JournalBone Marrow Transplantation
Volume53
Issue number8
DOIs
Publication statusPublished - 2018 Aug 1

Fingerprint

T-Cell Lymphoma
Stem Cell Transplantation
Taiwan
Adult T Cell Leukemia Lymphoma
Natural Killer T-Cells
Transplantation
Guidelines
Transplants
Drug Therapy
Neoplasms

All Science Journal Classification (ASJC) codes

  • Hematology
  • Transplantation

Cite this

Hsu, Ya-Ting ; Tsai, Hui Jen ; Chang, Jeffrey S. ; Li, Sin-Syue ; Tang, Jih Luh ; Yeh, Su Peng ; Hwang, Wen Li ; Liu, Jin Hwang ; Tan, Tran Der ; Wang, Po Nan ; Hsiao, Hui Hua ; Chen, Tsai-Yun. / Stem cell transplantation for T-cell lymphomas in Taiwan. In: Bone Marrow Transplantation. 2018 ; Vol. 53, No. 8. pp. 993-1000.
@article{89469b4bb7d24792bf33f890825c02ea,
title = "Stem cell transplantation for T-cell lymphomas in Taiwan",
abstract = "T-cell lymphomas are generally aggressive malignancies with poor prognosis. There are no standard treatment guidelines for T-cell lymphomas, and the timing of stem cell transplantation (SCT) is not well known. In this study, we investigated the outcomes of Taiwanese patients with T-cell lymphomas after SCT. We retrospectively analyzed 131 patients with T-cell lymphomas receiving SCT (autologous: 90, allogeneic: 41) from 2009 to 2014. More autologous SCT recipients were ALCL or in complete remission, and more allogeneic recipients had advanced disease. 56 patients who were sensitive to chemotherapy underwent SCT as upfront setting. The 2-year PFS and OS rates were 67.0 and 64.5{\%}, respectively. Regarding disease status before transplantation, patients with CR1 had the best outcomes. Among different subtypes, patients with natural killer/T-cell lymphomas showed the worst outcomes, with 2-year OS rate of 23.5{\%}. The OS rates for the other three major subtypes were as follows: 72.9{\%} for ALCL; 75.0{\%} for AITL; and 51.4{\%} for PTCL-NOS. For more rare subtypes, such as ATLL and SPTCL, data from our study show that SCT can be beneficial. We concluded that upfront autologous SCT is feasible and effective for patients with low PIT, and disease status at transplant is the strong predictor of outcome.",
author = "Ya-Ting Hsu and Tsai, {Hui Jen} and Chang, {Jeffrey S.} and Sin-Syue Li and Tang, {Jih Luh} and Yeh, {Su Peng} and Hwang, {Wen Li} and Liu, {Jin Hwang} and Tan, {Tran Der} and Wang, {Po Nan} and Hsiao, {Hui Hua} and Tsai-Yun Chen",
year = "2018",
month = "8",
day = "1",
doi = "10.1038/s41409-018-0116-6",
language = "English",
volume = "53",
pages = "993--1000",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "8",

}

Hsu, Y-T, Tsai, HJ, Chang, JS, Li, S-S, Tang, JL, Yeh, SP, Hwang, WL, Liu, JH, Tan, TD, Wang, PN, Hsiao, HH & Chen, T-Y 2018, 'Stem cell transplantation for T-cell lymphomas in Taiwan', Bone Marrow Transplantation, vol. 53, no. 8, pp. 993-1000. https://doi.org/10.1038/s41409-018-0116-6

Stem cell transplantation for T-cell lymphomas in Taiwan. / Hsu, Ya-Ting; Tsai, Hui Jen; Chang, Jeffrey S.; Li, Sin-Syue; Tang, Jih Luh; Yeh, Su Peng; Hwang, Wen Li; Liu, Jin Hwang; Tan, Tran Der; Wang, Po Nan; Hsiao, Hui Hua; Chen, Tsai-Yun.

In: Bone Marrow Transplantation, Vol. 53, No. 8, 01.08.2018, p. 993-1000.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Stem cell transplantation for T-cell lymphomas in Taiwan

AU - Hsu, Ya-Ting

AU - Tsai, Hui Jen

AU - Chang, Jeffrey S.

AU - Li, Sin-Syue

AU - Tang, Jih Luh

AU - Yeh, Su Peng

AU - Hwang, Wen Li

AU - Liu, Jin Hwang

AU - Tan, Tran Der

AU - Wang, Po Nan

AU - Hsiao, Hui Hua

AU - Chen, Tsai-Yun

PY - 2018/8/1

Y1 - 2018/8/1

N2 - T-cell lymphomas are generally aggressive malignancies with poor prognosis. There are no standard treatment guidelines for T-cell lymphomas, and the timing of stem cell transplantation (SCT) is not well known. In this study, we investigated the outcomes of Taiwanese patients with T-cell lymphomas after SCT. We retrospectively analyzed 131 patients with T-cell lymphomas receiving SCT (autologous: 90, allogeneic: 41) from 2009 to 2014. More autologous SCT recipients were ALCL or in complete remission, and more allogeneic recipients had advanced disease. 56 patients who were sensitive to chemotherapy underwent SCT as upfront setting. The 2-year PFS and OS rates were 67.0 and 64.5%, respectively. Regarding disease status before transplantation, patients with CR1 had the best outcomes. Among different subtypes, patients with natural killer/T-cell lymphomas showed the worst outcomes, with 2-year OS rate of 23.5%. The OS rates for the other three major subtypes were as follows: 72.9% for ALCL; 75.0% for AITL; and 51.4% for PTCL-NOS. For more rare subtypes, such as ATLL and SPTCL, data from our study show that SCT can be beneficial. We concluded that upfront autologous SCT is feasible and effective for patients with low PIT, and disease status at transplant is the strong predictor of outcome.

AB - T-cell lymphomas are generally aggressive malignancies with poor prognosis. There are no standard treatment guidelines for T-cell lymphomas, and the timing of stem cell transplantation (SCT) is not well known. In this study, we investigated the outcomes of Taiwanese patients with T-cell lymphomas after SCT. We retrospectively analyzed 131 patients with T-cell lymphomas receiving SCT (autologous: 90, allogeneic: 41) from 2009 to 2014. More autologous SCT recipients were ALCL or in complete remission, and more allogeneic recipients had advanced disease. 56 patients who were sensitive to chemotherapy underwent SCT as upfront setting. The 2-year PFS and OS rates were 67.0 and 64.5%, respectively. Regarding disease status before transplantation, patients with CR1 had the best outcomes. Among different subtypes, patients with natural killer/T-cell lymphomas showed the worst outcomes, with 2-year OS rate of 23.5%. The OS rates for the other three major subtypes were as follows: 72.9% for ALCL; 75.0% for AITL; and 51.4% for PTCL-NOS. For more rare subtypes, such as ATLL and SPTCL, data from our study show that SCT can be beneficial. We concluded that upfront autologous SCT is feasible and effective for patients with low PIT, and disease status at transplant is the strong predictor of outcome.

UR - http://www.scopus.com/inward/record.url?scp=85041922984&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041922984&partnerID=8YFLogxK

U2 - 10.1038/s41409-018-0116-6

DO - 10.1038/s41409-018-0116-6

M3 - Article

C2 - 29434288

AN - SCOPUS:85041922984

VL - 53

SP - 993

EP - 1000

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 8

ER -